EichorEICHOR
Location: The Woodlands Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near The Woodlands

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · US Oncology Research Network · Eli Lilly and Company · NCT07218380This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Renovatio Clinical · Pfizer · NCT06758401Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3 · Advanced Rheumatology of Houston - The Woodlands · Takeda · NCT06671496A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Renovatio Clinical · Hoffmann-La Roche · NCT06793215Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · Texas Oncology - Gulf Coast · Pfizer · NCT07421700A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · Texas Oncology-The Woodlands ( Site 8000) · Merck Sharp & Dohme LLC · NCT07216703Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · USO - US Oncology Research Network · Eli Lilly and Company · NCT06890598A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Texas Oncology - Gulf Coast · Pfizer · NCT07144280A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Phase 3 · Renovatio Clinical - The Woodlands Research Center · UroGen Pharma Ltd. · NCT06774131Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · NRG Oncology · NCT05946213Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophreni
Phase 3 · Family Psychiatry of The Woodlands · Gedeon Richter Plc. · NCT03817502A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 3 · Texas Oncology Gulf Coast · Takeda · NCT06499285ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Houston Methodist The Woodlands Hospital · Alliance for Clinical Trials in Oncology · NCT06876714GEMINI-NSCLC: NSCLC Biomarker Study
Phase N/A · Tempus AI · NCT05236114Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Houston Methodist The Woodlands Hospital · Canadian Cancer Trials Group · NCT06592924A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Phase 2 · Advanced Rheumatology of Houston ( Site 0001) · Merck Sharp & Dohme LLC · NCT07133633Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica
Phase 1/Phase 2 · Texas Oncology - Gulf Coast · Pfizer · NCT07227415A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary
Phase 3 · Retina Consultants of Texas (Woodlands) · Kodiak Sciences Inc · NCT06990399An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · Novartis Pharmaceuticals · NCT05939414A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · Texas Oncology · Verastem, Inc. · NCT06072781Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipol
Phase 2 · Family Psychiatry Of The Woodlands /ID# 278050 · AbbVie · NCT07220460Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Houston Methodist The Woodlands Hospital · National Cancer Institute (NCI) · NCT05256225Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · Texas Oncology - Gulf Coast · Revolution Medicines, Inc. · NCT06881784Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Phase 3 · Houston Methodist The Woodlands Hospital · NRG Oncology · NCT05646316Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geog
Phase 1/Phase 2 · Retina Consultants - The Woodlands /ID# 262138 · AbbVie · NCT07160179Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Texas Oncology - Gulf Coast · Pfizer · NCT07222800De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Houston Methodist The Woodlands Hospital · NRG Oncology · NCT04852887A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · Renovatio Clinical · Hoffmann-La Roche · NCT05894239
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.